Novonorm (Repaglinide)

Repaglinide, the active ingredient in Novonorm, is a meglitinide presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients by enhancing insulin secretion after meals. It works by binding to pancreatic beta‑cell K‑ATP channels, leading to rapid insulin release that helps control post‑prandial glucose levels.

GNH USA supplies Novonorm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets.

Repaglinide is used to manage hyperglycemia within the type 2 diabetes mellitus therapeutic pathway.

- Type 2 diabetes mellitus: improves overall glycemic control when combined with diet and exercise. - Post‑meal hyperglycemia: reduces glucose spikes after meals. - Adjunct therapy: complements other oral antidiabetic agents to achieve target HbA1c.

Repaglinide may cause several adverse reactions, ranging from mild to serious.

Common Side Effects: - Hypoglycemia: low blood sugar, especially if meals are missed. - Nausea: mild stomach upset. - Diarrhea: loose stools. - Headache: mild to moderate pain. - Dizziness: sensation of lightheadedness.

Serious or Rare Side Effects: - Severe hypoglycemia: confusion, loss of consciousness, seizures. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Liver dysfunction: elevated transaminases, jaundice. - Pancreatitis: abdominal pain, nausea, vomiting.

When prescribing Repaglinide, clinicians should consider several safety measures.

- Meal timing: take the tablet shortly before meals to match insulin release. - Renal impairment: adjust dose or monitor closely in patients with reduced kidney function. - Hepatic impairment: use with caution in liver disease due to altered metabolism. - Concomitant sulfonylureas: avoid combined use to reduce risk of severe hypoglycemia. - Pregnancy and lactation: assess risk‑benefit; limited data available. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Repaglinide interacts with several drugs that may alter its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may increase Repaglinide plasma levels, risking hypoglycemia. - Other insulin secretagogues (e.g., sulfonylureas): additive hypoglycemic effect. - MAO‑B inhibitors: potential for enhanced hypoglycemia.

Moderate Interactions (Monitor Closely): - CYP2C8 inducers (e.g., rifampin): may reduce drug exposure, decreasing efficacy. - Beta‑blockers: may mask hypoglycemia symptoms. - NSAIDs (high dose): may affect renal function, influencing drug clearance. - Alcohol: can potentiate hypoglycemia, especially with missed meals.